Triochem Products Limited has filed its quarterly Statement of Deviation or Variation in Public Issue with BSE Limited for the quarter ended December 31, 2025, in compliance with Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The submission was made on February 13, 2026, by Director Ramu S. Deora.

Regulatory Compliance Filing

The statement confirms that the company did not undertake any fund raising activities during the quarter ended December 31, 2025. The filing indicates that no public issues, rights issues, preferential issues, or other fund raising mechanisms were utilized by the company during this period.

Audit Committee and Auditor Comments

The Audit Committee provided specific comments regarding the filing, stating that "the statement of Category wise variation is also not applicable as there has been no offer made by way of Public Issue, Rights Issue, Preferential Issue, etc., during the Quarter ended 31st December 2025."

Similarly, the company's auditors confirmed the non-applicability of the statement, noting that "there is no offer made by way of Public Issue, Right Issue, Preferential Issue, etc."

Company Information

Triochem Products Limited operates from its registered office at 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra. The company trades on BSE with security code 512101 and ISIN number INE331E01013. The filing was signed by Ramu S. Deora, Director with DIN 00312369, ensuring proper authorization and compliance with regulatory requirements.

The submission follows the amended guidelines as per SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, demonstrating the company's commitment to maintaining transparency and regulatory compliance in its financial reporting obligations.

Triochem Products Limited has filed its quarterly statement of defaults with BSE Limited, reporting a clean debt profile for the quarter ended December 31, 2025. The Mumbai-based pharmaceutical company submitted the mandatory disclosure under SEBI Listing Obligations and Disclosure Requirements Regulations 2015 on January 7, 2026.

Debt Position Summary

The company's financial position reflects zero outstanding debt across all categories during the reporting quarter. The comprehensive statement covers loans from banks and financial institutions, unlisted debt securities, and total financial indebtedness.

Regulatory Compliance

The filing was made in accordance with BSE Circular No. LIST/COMP/50/2019-20 dated January 15, 2020, which mandates listed companies to disclose their debt default status quarterly. Company Secretary and Compliance Officer Ureca Deolekar signed the statement digitally, ensuring proper authentication of the submitted information.

Company Background

Triochem Products Limited operates from its registered office at Sambava Chambers, Fort, Mumbai, with Corporate Identity Number L24249MH1972PLC015544. The company trades on BSE under security code 512101 with ISIN number INE331E01013. The pharmaceutical sector entity maintains its corporate website at www.triochemproducts.com and can be reached at info@amphray.com .

Financial Health Indicator

The zero debt position across all categories indicates the company's conservative financial approach during the quarter ended December 31, 2025. This debt-free status eliminates concerns about interest payment defaults or principal repayment issues that could impact shareholder value or regulatory standing.